Cardio-hepatic metabolic derangements and valproic acid

Gianluigi Mazzoccoli, Calogero Longhitano, Manlio Vinciguerra

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Valproic acid (VPA) is an anti-epileptic and mood-stabilizing compound successfully used in the clinics since many decades. During the last few years, research on VPA revitalized. VPA has profound impact on nuclear chromatin structure in target cells by impinging on epigenetic mechanisms such as inhibition of histone deacetylase HDAC1, with implications for HIV and cancer treatment, and for the direct reprogramming in generation of induced pluripotent stem (iPS) cells. VPA can thus act at multiple levels and in several cellular systems. In addition to its established applications for the treatment of neurological and psychiatric disorders, and its newly discovered epigenetic mechanisms of action, the peripheral metabolic effects of VPA administration, in particular impinging on the heart and on the liver, are now starting to be understood. These have important consequences for the management of therapy and also for investigation purposes. The aim of this article is on one hand to summarize the emerging knowledge on the role of VPA during the occurrence of cardio-metabolic dysfunctions and on the other hand to describe concisely the VPA-induced epigenetic modifications in target cells.

Original languageEnglish
Pages (from-to)165-170
Number of pages6
JournalCurrent Clinical Pharmacology
Volume9
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Valproic Acid
Liver
Epigenomics
Histone Deacetylase 1
Induced Pluripotent Stem Cells
Nervous System Diseases
Chromatin
Psychiatry
HIV
Research
Neoplasms

Keywords

  • Epigenetics
  • Heart
  • Histone deacetylases
  • Lipid metabolism
  • Liver
  • Valproic acid

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Medicine(all)

Cite this

Cardio-hepatic metabolic derangements and valproic acid. / Mazzoccoli, Gianluigi; Longhitano, Calogero; Vinciguerra, Manlio.

In: Current Clinical Pharmacology, Vol. 9, No. 2, 2014, p. 165-170.

Research output: Contribution to journalArticle

Mazzoccoli, Gianluigi ; Longhitano, Calogero ; Vinciguerra, Manlio. / Cardio-hepatic metabolic derangements and valproic acid. In: Current Clinical Pharmacology. 2014 ; Vol. 9, No. 2. pp. 165-170.
@article{7b31e7b18e974cd2a5c4bc394fb70e12,
title = "Cardio-hepatic metabolic derangements and valproic acid",
abstract = "Valproic acid (VPA) is an anti-epileptic and mood-stabilizing compound successfully used in the clinics since many decades. During the last few years, research on VPA revitalized. VPA has profound impact on nuclear chromatin structure in target cells by impinging on epigenetic mechanisms such as inhibition of histone deacetylase HDAC1, with implications for HIV and cancer treatment, and for the direct reprogramming in generation of induced pluripotent stem (iPS) cells. VPA can thus act at multiple levels and in several cellular systems. In addition to its established applications for the treatment of neurological and psychiatric disorders, and its newly discovered epigenetic mechanisms of action, the peripheral metabolic effects of VPA administration, in particular impinging on the heart and on the liver, are now starting to be understood. These have important consequences for the management of therapy and also for investigation purposes. The aim of this article is on one hand to summarize the emerging knowledge on the role of VPA during the occurrence of cardio-metabolic dysfunctions and on the other hand to describe concisely the VPA-induced epigenetic modifications in target cells.",
keywords = "Epigenetics, Heart, Histone deacetylases, Lipid metabolism, Liver, Valproic acid",
author = "Gianluigi Mazzoccoli and Calogero Longhitano and Manlio Vinciguerra",
year = "2014",
doi = "10.2174/1574884708999140101144839",
language = "English",
volume = "9",
pages = "165--170",
journal = "Current Clinical Pharmacology",
issn = "1574-8847",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Cardio-hepatic metabolic derangements and valproic acid

AU - Mazzoccoli, Gianluigi

AU - Longhitano, Calogero

AU - Vinciguerra, Manlio

PY - 2014

Y1 - 2014

N2 - Valproic acid (VPA) is an anti-epileptic and mood-stabilizing compound successfully used in the clinics since many decades. During the last few years, research on VPA revitalized. VPA has profound impact on nuclear chromatin structure in target cells by impinging on epigenetic mechanisms such as inhibition of histone deacetylase HDAC1, with implications for HIV and cancer treatment, and for the direct reprogramming in generation of induced pluripotent stem (iPS) cells. VPA can thus act at multiple levels and in several cellular systems. In addition to its established applications for the treatment of neurological and psychiatric disorders, and its newly discovered epigenetic mechanisms of action, the peripheral metabolic effects of VPA administration, in particular impinging on the heart and on the liver, are now starting to be understood. These have important consequences for the management of therapy and also for investigation purposes. The aim of this article is on one hand to summarize the emerging knowledge on the role of VPA during the occurrence of cardio-metabolic dysfunctions and on the other hand to describe concisely the VPA-induced epigenetic modifications in target cells.

AB - Valproic acid (VPA) is an anti-epileptic and mood-stabilizing compound successfully used in the clinics since many decades. During the last few years, research on VPA revitalized. VPA has profound impact on nuclear chromatin structure in target cells by impinging on epigenetic mechanisms such as inhibition of histone deacetylase HDAC1, with implications for HIV and cancer treatment, and for the direct reprogramming in generation of induced pluripotent stem (iPS) cells. VPA can thus act at multiple levels and in several cellular systems. In addition to its established applications for the treatment of neurological and psychiatric disorders, and its newly discovered epigenetic mechanisms of action, the peripheral metabolic effects of VPA administration, in particular impinging on the heart and on the liver, are now starting to be understood. These have important consequences for the management of therapy and also for investigation purposes. The aim of this article is on one hand to summarize the emerging knowledge on the role of VPA during the occurrence of cardio-metabolic dysfunctions and on the other hand to describe concisely the VPA-induced epigenetic modifications in target cells.

KW - Epigenetics

KW - Heart

KW - Histone deacetylases

KW - Lipid metabolism

KW - Liver

KW - Valproic acid

UR - http://www.scopus.com/inward/record.url?scp=84921424733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921424733&partnerID=8YFLogxK

U2 - 10.2174/1574884708999140101144839

DO - 10.2174/1574884708999140101144839

M3 - Article

VL - 9

SP - 165

EP - 170

JO - Current Clinical Pharmacology

JF - Current Clinical Pharmacology

SN - 1574-8847

IS - 2

ER -